Project Grant R43HL184460
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $606K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Tucson, AZ 85713, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Pulsentry, Inc. $309,198 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and prototype an automated detection system for cardiac tamponade using existing fingertip pulse oximeters. Pulsentry will develop machine learning algorithms that analyze pulse waveform perturbations to identify early signs of cardiac tamponade, a medical emergency caused by fluid or clot accumulation around the heart...
- Federal Project Grant Award Summary Perfusion Solutions Inc. received a $320,838 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 5, 2025, with completion targeted for February 28, 2027. The award supports Phase I development of a fail-safe, high-output cavopulmonary assist pump designed for pediatric and congenital heart disease patients with single ventricle physiology...
- The National Heart, Lung, and Blood Institute awarded Perfusion Solutions Inc. $217,013 on August 1, 2026, to develop a bearingless, fail-safe pump for patients with single ventricle physiology following Fontan surgical palliation under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds Phase I research to design and develop a bearingless motor integrated into a centrifugal pump rotor, with the pump's stator incorporating the motor stator. The device is engineered to...
- The National Heart, Lung, and Blood Institute awarded Resuscitation Innovations LLC $396,098 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and test an adjustable-pressure impedance threshold device for cardiac arrest resuscitation and post-resuscitation care. The recipient will refine the design of the Adjustable Pressure for Emergency Care (APEC) device, a dual-setting airway device with selectable cracking pressures of -6 and -12 centimeters of...
- The National Heart, Lung, and Blood Institute awarded Autonomous Healthcare Inc. $305,999 on September 1, 2026, under the Small Business Innovation Research (SBIR) program to conduct a Phase I feasibility study of E-Fusion, a bedside clinical decision support system designed to assist anesthesiologists, anesthetists, and critical care nurses with vasopressor titration and blood pressure management during surgery and in the intensive care unit. The system monitors mean arterial pressure (MAP) and...
- The National Heart, Lung, and Blood Institute awarded $351,388 to Barron Associates, Inc. on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a noninvasive hemodynamic monitoring tool for heart failure patients. The project addresses the clinical gap in home and hospital monitoring of acute decompensated heart failure by creating a low-cost alternative to invasive right heart catheterization and costly implantable devices. The proposed solution...
- The National Heart, Lung, and Blood Institute awarded Corvion, Inc. $2,999,968 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a novel pediatric left ventricular assist device (P-LVAD) enabling children with end-stage heart failure to discharge home while awaiting heart transplantation or living long-term with the device. This is a Project Grant (SBIR Phase II). Corvion will engineer an implantable, ultra-low-power blood pump combining hydrodynamic...
- The National Heart, Lung, and Blood Institute awarded Inflo Medical Inc. $595,332 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to optimize its MOBYBOX extracorporeal membrane oxygenation (ECMO) platform for pediatric use. Inflo Medical is redesigning the MOBYBOX's gas exchanger and pulsatile displacement pump to reduce thrombogenicity and hemolysis in pediatric patients. The Phase I Small Business Innovation Research effort focuses on two complementary...
- The National Heart, Lung, and Blood Institute awarded $598,636 to Spheric Bio Inc. on September 25, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop the EMULAATE platform, a patient-specific left atrial appendage occlusion (LAAO) device for stroke prevention in atrial fibrillation patients. Spheric Bio is developing EMULAATE to assemble fully soft, personalized implants directly inside the patient's body through a minimally invasive approach by delivering,...
- Percassist Inc. received a $663,129 Project Grant award from the National Heart Lung and Blood Institute of the Department of Health and Human Services. The award was made under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research. The grant funds the development of a percutaneous ventricular assist device for chronic heart failure patients. Specifically, Percassist will design and test a balloon catheter implant that can be delivered minimally...